Company: MVIS
Filing Date: 2025-02-03
Form Type: 424B5
Source: 0001493152-25-004622
Chunk: 5

Company: MICROVISION, INC.
Filing Date: 2025-02-03
Form: 424B5
Chunk 5
---
us supplement or the accompanying prospectus.

| S-2 |

<div align='center'>The Offering</div>

| Common              
 stock offered by us |     | 5,750,225 
 shares.   |

| Common                                                     
 stock to be outstanding immediately after this offering(1) |     | 230,731,480                                                                                                                           
 shares.                                                                                                                               |
| Warrants                                                   
 we are offering                                            |     | We                                                                                                                                    
 are offering warrants to purchase up to 5,750,225 shares of common stock, which will be exercisable at any time on or after           
 the earlier of (i) the date that is six months after the date of issuance and (ii) the date that the Requisite Stockholder Approval   
 (as defined in that certain Senior Secured Convertible Note due 2026, Certificate No. A-1, issued to the investor by the Company      
 on October 23, 2024) is obtained at an exercise price per share equal to $1.57. This prospectus supplement also relates to            
 the offering of the shares of common stock issuable upon exercise of the warrants. For additional information regarding the warrants, 
 see “Description of Securities We are Offering—Warrants.”                                                                             |

| Listing |     | Our                                                                                                                              
 common stock is listed on the Nasdaq Global Market under the symbol “MVIS.” There is no established public trading market        
 for the warrants and we do not expect a market to develop. In addition, we do not intend to apply for listing of the warrants on 
 any national securities exchange or other nationally recognized trading system.                                                  |

| Use         
 of proceeds |     | We                                                                                                                                    
 intend to use the net proceeds from the sale of common stock and warrants offered by this prospectus supplement for general corporate 
 purposes, which may include, but are not limited to, working capital and capital expenditures. See “Use of Proceeds.”                 |

| Risk    
 factors |     | Investing                                                             
 in our securities involves a high degree of risk. See “Risk Factors.” |

(1) The number of shares of common stock to be outstanding after this offering is based on 224,981,255 shares of our common stock outstanding as of January 30, 2025 and excludes, as of that date, the following:

| ● | 666,058                                                                                                                       
 shares of our common stock issuable upon exercise of outstanding options, all of which were exercisable at a weighted average 
 exercise price of $1.43 per share